Abstract: A novel strain of Bacillus subtilis EB120 shows high antagonistic activity for controlling various plant diseases including barley powdery mildew, cucumber powdery mildew, red pepper anthracnose, rice blast, tomato gray mold, tomato late blight and wheat leaf rust, it can be effectively used as a microbioside for biologically controlling the plant diseases.

Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18?19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase derma-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.

Abstract: The invention relates to a cosmetic based on various natural raw materials, which can be used to counter ageing processes of the human skin. The inventive cosmetic contains 0.1-5% by weight of an extract from a mixture of fig leaves and fruits, 0.1-3% by weight of an extract from pomegranate fruits, 0.001-0.5% by weight of a ground dry mixture of rosemary stems and leaves, 0.01-3% by weight of liposomes containing an extract from peeled musk melons, 0.1-5% by weight of liposomes containing a plankton extract containing the photolyase enzyme, 0.1-5% by weight of liposomes containing 0.1 to 0.5% by weight, in relation to the liposome weight, of a micrococcus lysate containing the UV-endonuclease enzyme; and up to 100% by weight, other active substances, carrier substances, adjuvants or mixtures thereof.

Abstract: The present invention relates to a preventive and/or a therapeutic agent for inflammatory bowel diseases containing a fermentation product of a propionic acid bacterium as an active ingredient.

Abstract: The present invention relates to a method of modulating a selected biological activity of a naturally occurring material having one or more biological activities in an extract of the naturally occurring material, the method comprising incubating the extract in a medium in the presence of an aerobically metabolizing microorganism, under suitable aerobic conditions, for a period of time sufficient to modulate the selected activity with respect to baseline activity of the unincubated extract. The invention also relates to the bioconverted material so prepared, and the use of same in cosmetic or pharmaceutical compositions.

Abstract: The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 ?mol glycodeoxycholic acid (GDCA)/gram/hour and >2 ?mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 ?mol GDCA/g/hr and >7 ?mol TDCA/g/hr when measured over 30 minutes.

Abstract: A process for the preparation of a non-viable probiotic composition having anti-allergic (i.e. allergy preventive and/or anti-allergic in a therapeutic sense) properties, the process including the steps of (a) subjecting LGG to cultivation in a suitable culture medium using a batch process; (b) harvesting the culture supernatant at a late exponential phase of the cultivation step; (c) removing liquid contents from the culture supernatant so as to obtain the composition. Also, a composition comprising a proteinaceous mixture, said composition being obtainable by the above process, and the use thereof in a dietetic product preferably for targeting expecting mother's, infants, or children as well as application in food for specific medical purposes.

Abstract: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria.

Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.

Abstract: The invention relates to microbiological processes using non-selenium-respiring bacteria for the production of elemental selenium nanospheres having a size in the 50-500 nm range and compositions comprising said nanospheres. The invention further concerns grey elemental selenium nanospheres directly obtainable by the processes of the invention. The compositions and materials of the invention are useful, in particular, as food additives and for use as raw material in the microelectronic and optical industries.

Abstract: The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals.

Abstract: Cosmetic or dermopharmaceutical compositions containing Pseudoalteromonas ferment extract for the treatment and/or care of the skin, scalp and/or nails, preferably to improve the barrier function of the skin, scalp and/or nails, and specifically for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, scalp and/or nails associated with an alteration in the keratinization process.

Abstract: Use of bacterial cells of the genus Tenacibaculum, from the crude cellular extract or from its cultivation supernatants, capable of degrading N-acyl homoserine lactones, for quorum quenching, for treatment of infectious bacterial illnesses or to inhibit formation of biofilms.

Abstract: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises two or more active ingredients selected from the group consisting of a) dipalmitoyl hydroxyproline, salts and esters thereof; b) carnitine; and c) an extract of Haematococcus pluvialis. Compositions prepared in accordance with the invention are useful for improving the appearance of the skin.

Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).

Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.

Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.

Abstract: An object is to provide a more potent novel antimicrobial active substance, which is derived from a naturally occurring substance and has a broad antimicrobial spectrum, and an antimicrobial active substance DM0507 obtained by a production process comprising the following steps (a) to (d): (a) culturing Bacillus subtilis; (b) collecting the supernatant from the obtained culture; (c) collecting the precipitate formed by adjusting the pH of the supernatant to 3 or lower; and (d) performing extraction from the precipitate with ethanol is provided.

Abstract: A blood-viscosity reducing agent contains a protein derived from Bacillus subtilis natto and including, sequentially from an amino group terminal, a first structural amino acid sequence having alanine, threonine, aspartic acid, glycine, valine, glutamic acid, tryptophan, asparagine, valine, aspartic acid, glutamine, isoleucine, aspartic acid, alanine, proline, lysine, alanine, tryptophan, alanine, leucine, glycine, tyrosine aspartic, acid, glycine, threonine, glycine, threonine, valine, valine, alanine, serine, isoleucine, aspartic acid, threonine, glycine, valine, glutamic acid, tryptophan, asparagine, histidine, proline, alanine, leucine, lysine, glutamic acid, lysine, tyrosine, arginine, glycine, tyrosine, asparagine, proline, glutamic acid, asparagine, proline, asparagine, glutamic acid, proline, glutamic acid, asparagine, glutamic acid, methionine, asparagine, tryptophan, tyrosine, aspartic acid, alanine, valine, alanine, glycine, glutamic acid, alanine, serine, proline, tyrosine, aspartic acid, aspartic

Abstract: The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content.

Abstract: A lactic composition containing at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei and a mixture of Lactobacillus acidophilus and Lactobacillus casei, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.

Abstract: The present invention relates to a method for the cosmetic treatment of a keratin material comprising at least the steps of: (a) having available a lyophilizate containing at least one live or inactivated, physiologically acceptable microorganism, one of its metabolites or one of its fractions and at least one surfactant with an HLB greater than or equal to 12, (b) having available a physiologically acceptable medium, separate from the said lyophilizate, (c) bringing the said lyophilizate extemporaneously into contact with the said medium under conditions favourable for the solubilization and/or dispersion of the said lyophilizate in the said medium, and (d) bringing the mixture obtained in the preceding step into contact with the said keratin material. It further relates to a lyophilizate as defined above.

Abstract: The invention relates to a novel strain of Lactobacillus paracasei subspecies paracasei, having antimicrobial and immunomodulatory properties, and to compositions containing said strain.

Abstract: The invention relates to adhesives for medical applications and methods of their preparation and use.

Abstract: There are disclosed skin treatment compositions containing cell signaling compounds, which induce and promote the biosynthesis and/or bioactivity of endogenous chemicals that mediate cell to cell communication in the skin between keratinocytes, fibroblasts and other cell types present in the skin. The cell signaling compound is selected from the group consisting of: andrographolide and its derivatives; adenosine cyclic phosphate and its derivatives; hydrolyzed milk proteins; sunflower seed extract; plankton extract; phytol and its derivatives; and mixtures thereof.

Abstract: Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

Abstract: Disclosed is an intestinal environment-improving agent including a lactoferrin and bacteria of Lactobacillus brevis as effective ingredients.

Abstract: The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.

Abstract: Disclosed are microcapsules with shells that are not animal by-products and methods for preparing and using such microcapsules.

Abstract: Described are microorganism which are able to reduce the generation of feces odor by decreasing the amount of at least one of the compounds methyl mercaptan, a sulphide compound, cadavarine, putrescine, indole or skatole, and wherein said decrease in the amount of said compounds is independent of the growth of the microorganism. Also described are compositions, comprising such microorganisms, e.g. food, feed or pharmaceutical compositions and the use of such microorganisms for suppressing feces odor or the preparation of foodstuff or feedstuff, as well as corresponding methods for the production of food or feed composition and additives for food, feed or drinks.

Abstract: The present patent application relates to a composition for topical application in the form of an oil-in-water emulsion comprising an oily phase dispersed in an aqueous phase, characterized in that it comprises at least one noncrosslinked amphiphilic polymer, the globules of the said emulsion exhibiting a mean size ranging from 15 to 500 microns and the oily phase being present in an amount of less than 35% by weight, with respect to the total weight of the composition.

Abstract: A composition for deicing or for the preparation of a heat transfer fluid is provided. The composition comprises a mixture of at least two carboxylic acid salts having a t/c ratio of 2 or lower, including a dicarboxylic salt and a monocarboxylic salt, said dicarboxylic salt being present in the mixture in an amount of at least 50 wt % of the weight of the mixture, on a dry basis. More particularly, said mixture is including a succinate and a formate, wherein the succinate is in an amount of at least 50 wt %, on a dry basis. Also provided is a method for deicing a surface or preventing the accumulation of ice, snow or a mixture thereof on a surface, comprising a step of applying on a surface covered by ice, snow or a mixture thereof, or susceptible of being covered by ice, snow or a mixture thereof, the above composition. The composition is also useful for the preparation of a heat transfer fluid coolant to be used in a heat transfer system comprising a heat transfer fluid provided with a cooling system.

Abstract: The disclosed subject matter, in one aspect, relates to compounds and compositions {e.g., polysaccharides and polysaccharide complexes) and methods for providing and using such compounds and compositions. Disclosed are compositions comprising a polysaccharide or polysaccharide complex obtained from Chlorella, wherein the polysaccharide or polysaccharide complex has a molecular weight of from about 1×103 to about 1×106 Da. Also disclosed are methods of providing a polysaccharide or polysaccharide complex, comprising the steps of providing a Chlorella extract, contacting the extract with a solvent to provide a precipitate, contacting the precipitate with additional substances {e.g., a surfactant) and isolating an insoluble fraction, and size fractioning the insoluble fraction, thereby providing the polysaccharide or polysaccharide complex. Disclosed are also methods for using the disclosed polysaccharide and polysaccharide compositions.

Abstract: The present invention is an oral dosage composition for prevention and treatment of hepatic inflammation such as NASH. The present invention is an oral dosage composition for prevention or treatment of hepatic inflammation, contains the radical scavenging active spirulina powder effective in preventing, ameliorating, and curing NASH or the like.

Abstract: The method is for treating a marine object. A composition is provided that has an organic substance. The composition is applied to the marine object. The composition has a first layer and a second layer. A first organic substance on the first layer attracts bacteria. The bacteria consume the first organic substance and during this process use oxygen. The bacteria thus reduce an oxygen level in a boundary layer adjacent to a surface of the marine object. The first layer of the composition erodes to expose the second layer. The bacteria consume a second organic substance of the second layer.

Abstract: The invention relates to a process for the preparation of a cosmetic or dermatological active principle, comprising the culturing of at least one nonphoto-synthetic and nonfruiting filamentous bacterium on a medium comprising at least one nonsulphurous mineral and/or thermal water. It also relates to a cosmetic or dermatological composition comprising at least one bacterium of the genus Vitreoscilla or one of its extracts.

Abstract: The invention relates to a novel strain of Lactobacillus rhamnosus, having antimicrobial and immunomodulatory properties, and to compositions containing said strain.

Abstract: The invention relates to the pharmaceutical composition for the treatment of a brain tumor, which contains in an effective amount from pharmaceutical point of view Peptidtoxin from spiders, Sicarius species and/or the saliva of the vipers from the Elaphe species; and the total poison or part of the spiders poison from the Latrodectus species, as well as the use of the pharmaceutical composition for the treatment of the brain tumor, a process for producing the pharmaceutical composition as well as a kit of parts containing the pharmaceutical composition.

Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.

Abstract: Preparation comprising Mycobacterium bovis BCG killed by Extended Freeze Drying (EFD) for preventing and/or treating rheumatoid arthritis.

Abstract: Composition and method for preventing, treating or attenuating inflammatory diseases by way of inhibiting lipid peroxidation and subsequent elementary inflammation through ensuring the presence of the following biologically active ingredients in the PMRS of cells involved in inflammation: i) at least one killed probiotic and ii) at least one omega 3 FA and iii) vitamin E and iv) ubiquinone by introducing a composition comprising any of the missing ingredients.

Abstract: To provide an agent promoting secretion and/or suppressing decrease of adiponectin, and an eating and drinking product and a feed promoting secretion and/or suppressing decrease of adiponectin. Provided are an agent promoting secretion and/or suppressing decrease of adiponectin, and a eating and drinking product and a feed promoting secretion and/or suppressing decrease of adiponectin, having as an active component a culture supernatant of Streptococcus, Lactobacillus, Propionibacterium, yeast, Leuconostoc, and Lactococcus.

Abstract: The invention relates to composition comprising a RPE and optionally a Th1-promoting adjuvant for the preparation of a medicament for the treatment or prevention of a parasitic disease and to its use.

Abstract: Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium lividumand a pharmaceutically acceptable carrier. Probiotic composition(s) and/or process(es) thereof may include relatively heat tolerant Janthinobacterium lividumwhich may produce metabolites, for example violacein up to approximately 29° C. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividumbetween approximately 25×106 and 6.4×107 cells. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividum which has and/or produces between approximately 18 ?M and 129 ?M of violacein. Probiotic composition(s) and/or process(es) thereof may include a stimulant to maximize metabolites.

Abstract: A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response mechanism.

Abstract: Infection of pathogens is controlled by inducing disease resistance with a method of treating a plant with a composition of an acidic heat-treated solution of microorganisms.

Abstract: Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R1, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Abstract: The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level. Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

Abstract: The invention relates to microorganisms for the treatment of food allergies, specifically coeliac disease, as well as to methods for the selection thereof. The action mechanisms of said microorganisms include: (i) the regulation of the innate and adaptive immunological responses; (ii) the reduction of the concentration of toxic gluten peptide epitopes in the intestinal lumen; (iii) the strengthening of the barrier defence function against harmful antigens and bacteria; and (iv) the provision of enzymatic activities that promote digestion.

Abstract: The invention relates to the use of lactic acid-producing bacteria to boost the immune system.